Who Paid My Doc
Christopher Anderson
Pulmonary Disease South Ogden, UT Medical Doctor
NPI 1497794150 CMS profile 889279
5957 Fashion Point Dr Ste 103, South Ogden, UT 84403
General payments
$196
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Christopher Anderson of South Ogden, UT is reported in the CMS Open Payments database as having received $196 across 7 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 20th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $15 | 1 | |
| 2023 | General | $99 | 1 | |
| 2021 | General | $37 | 2 | |
| 2020 | General | $34 | 2 | |
| 2019 | General | $12 | 1 |
Beside peers
- Christopher Anderson
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Christopher Anderson were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Christopher Anderson | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $12 | $377 | $109–$1,340 | $163 |
| 2020 | $34 | $230 | $56–$907 | $114 |
| 2021 | $37 | $269 | $68–$1,072 | $132 |
| 2022 | $0 | $390 | $100–$1,457 | $149 |
| 2023 | $99 | $419 | $114–$1,659 | $160 |
| 2024 | $15 | $476 | $123–$1,818 | $164 |
| 2025 | $0 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 20 billing codesPaid by Medicare
$35,620
Medicare patients
110
Services billed
390
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 52% | |
| Ischemic heart disease | 45% | |
| COPD | 42% | |
| Depression | 38% | |
| Heart failure | 37% | |
| Chronic kidney disease | 37% | |
| Diabetes | 36% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in Utah
Mary Scholand
Pulmonary Disease · Salt Lake City, UT
Talaat Al Shuqairat
Pulmonary Disease · Salem, UT
Charles Ivester
Pulmonary Disease · South Ogden, UT
Chakravarthy Reddy
Pulmonary Disease · Salt Lake City, UT
Timothy Leclair
Pulmonary Disease · Murray, UT
James Pearl
Pulmonary Disease · Salt Lake City, UT
Related records
Pulmonary Disease in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.